Clinical Trials Directory

Trials / Completed

CompletedNCT06223204

GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography

GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography - a Pilot Project

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Insel Gruppe AG, University Hospital Bern · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The GLEAM study aims at assessing the potential of electrical impedance tomography (EIT) for noninvasive glucose measurement.

Detailed description

Within the GLEAM study, paired samples of EIT and blood glucose measurements will be collected in individuals with type 1 diabetes during standardized euglycemia, hypoglycemia and hyperglycemia. These samples will be used to assess the potential of EIT for noninvasive glucose measurement and/or dysglycemia detection.

Conditions

Interventions

TypeNameDescription
OTHERControlled euglycemia, hypoglycemia and hyperglycemiaEIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.

Timeline

Start date
2024-01-31
Primary completion
2024-04-10
Completion
2024-04-10
First posted
2024-01-25
Last updated
2024-05-02

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT06223204. Inclusion in this directory is not an endorsement.